These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37157862)

  • 1. Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series.
    Meyerowitz EA; Mukerji SS; Kyle Harrold G; Erdil RM; Chen ST; Rudmann EA; Tsibris A; Venna N; Robbins GK
    Clin Infect Dis; 2023 Sep; 77(6):851-856. PubMed ID: 37157862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
    Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
    N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
    Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y
    Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
    Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
    J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
    Sato T; Nagai M; Watanabe O; Misu T; Takenouchi N; Ohkubo R; Ishihara S; Tsuboi Y; Katsuno M; Nakagawa M; Matsushita T; Aso Y; Matsuura E; Tokashiki T; Mukaino A; Adachi H; Nakanishi K; Yamaguchi Y; Yamaguchi S; Yamano Y
    J Neurol; 2024 Jun; 271(6):3471-3485. PubMed ID: 38430272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
    Gessain A; Mahieux R
    Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.
    Casseb J; de Oliveira AC; Vergara MP; Montanheiro P; Bonasser F; Meilman Ferreira C; Smid J; Duarte AJ
    J Med Virol; 2008 Mar; 80(3):392-8. PubMed ID: 18205234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Nakamura T; Nishiura Y; Eguchi K
    Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):137-49. PubMed ID: 20021347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Kodama D; Tanaka M; Matsuzaki T; Izumo K; Nakano N; Matsuura E; Saito M; Nagai M; Horiuchi M; Utsunomiya A; Takashima H; Kubota R; Izumo S
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008361. PubMed ID: 32667912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP.
    Grassi MF; Olavarria VN; Kruschewsky Rde A; Mascarenhas RE; Dourado I; Correia LC; de Castro-Costa CM; Galvão-Castro B
    J Med Virol; 2011 Jul; 83(7):1269-74. PubMed ID: 21567429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of T Regulatory Lymphocytes Transcription Factors in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Patients.
    Ghezeldasht SA; Sadeghian H; Azarpazhooh MR; Shamsian SAA; Rafatpanah H; Mahmoodi M; Rezaee SA
    Appl Biochem Biotechnol; 2017 Aug; 182(4):1403-1414. PubMed ID: 28101786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients.
    Varandas CMN; da Silva JLS; Primo JRL; de Oliveira MFSP; Moreno-Carvalho O; Farre L; Bittencourt AL
    Clin Infect Dis; 2018 Oct; 67(9):1427-1433. PubMed ID: 29912303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I.
    Puccioni-Sohler M; Yamano Y; Rios M; Carvalho SM; Vasconcelos CC; Papais-Alvarenga R; Jacobson S
    Neurology; 2007 Jan; 68(3):206-13. PubMed ID: 17224575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.
    Best I; Adaui V; Verdonck K; González E; Tipismana M; Clark D; Gotuzzo E; Vanham G
    Clin Exp Immunol; 2006 Nov; 146(2):226-33. PubMed ID: 17034574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Saito M; Matsuzaki T; Satou Y; Yasunaga J; Saito K; Arimura K; Matsuoka M; Ohara Y
    Retrovirology; 2009 Feb; 6():19. PubMed ID: 19228429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
    Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
    Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study.
    de Oliveira CJV; Neto JAC; Liberato de Matos SNF; Oliveira P; Tannus M; Castro N; Rocha PN; Carvalho EM
    J Sex Med; 2023 Feb; 20(3):269-276. PubMed ID: 36751985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.
    Adaui V; Verdonck K; Best I; González E; Tipismana M; Arévalo J; Vanham G; Campos M; Zimic M; Gotuzzo E
    J Neurovirol; 2006 Dec; 12(6):456-65. PubMed ID: 17162661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomicellar Curcumin Supplementation Improves the Clinical Manifestations of HAM/TSP Patients.
    Mohammadi A; Yazdi SZ; Poursina Z; Hampson IN; Vakili V; Sahebkar A; Akbarien MM; Rahimi H; Vakili R; Boostani R; Rafatpanah H
    Adv Exp Med Biol; 2021; 1328():347-359. PubMed ID: 34981488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Nozuma S; Kubota R; Jacobson S
    J Neurovirol; 2020 Oct; 26(5):652-663. PubMed ID: 32705480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.